SynthesisDisease markers2018
Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis.
Synthesis in Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.International journal of molecular sciences · 2023Article
- A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images.Scientific reports · 2023Article
- The Association of Single-Nucleotide Polymorphism rs13181 in ERCC2 with Risk and Prognosis of Nasopharyngeal Carcinoma in an Endemic Chinese Population.Pharmacogenomics and personalized medicine · 2021Article
- Impact of ERCC2 Gene Polymorphisms on OSCC Susceptibility and Clinical Characteristics.Global medical genetics · 2020Article
- Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes.Cancers · 2020Article
- Effect ofAmerican journal of translational research · 2020Article
- Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review.Pharmacogenomics and personalized medicine · 2020Review
- A Comprehensive Evaluation of the Association between Polymorphisms inJournal of oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral researchers have investigated the relationship between ERCC2 rs13181 and rs1799793 polymorphisms and chemotherapy efficacy in terms of tumour response and prognosis in gastric patients. However, the published data have shown inconsistencies.
methodsPubMed, Elsevier, and Chinese National Knowledge Infrastructure databases were searched for relevant articles published before August 1, 2017. Thirteen studies including 3096 gastric cancer patients treated with chemotherapy were included.
resultsFor rs1799793, in the overall analyses, no relationships were found between four genetic models and clinical response (AA vs. GG: OR = 1.17, 95% CI, 0.70-1.95; GA vs. GG: OR = 0.94, 95% CI, 0.69-1.27; GA + AA vs. GG: OR = 1.12, 95% CI, 0.85-1.46; and AA vs. GG + GA: OR = 1.24, 95% CI, 0.81-1.92). In stratified analyses, the results remained negative. We also found no relationship between each of the genetic models and overall survival time in the overall analyses. In the stratified analyses, for Asians, the A carrier genotype might be more closely associated with shorter survival time and higher risk of death for patients than the GG genotype (AA vs. GG: HR = 1.77, 95% CI, 1.20-2.6; GA + AA vs. GG: HR = 1.62, 95% CI, 1.26-2.09), but the results were negative for Caucasians. No significant relationships were found between the rs13181 polymorphism and OR or OS.
conclusionsThis meta-analysis suggested that the ERCC2 rs1799793 polymorphism might be a predictor of prognosis in gastric cancer patients subjected to platinum-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.